全文获取类型
收费全文 | 21917篇 |
免费 | 1405篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 751篇 |
妇产科学 | 367篇 |
基础医学 | 3119篇 |
口腔科学 | 559篇 |
临床医学 | 1972篇 |
内科学 | 4166篇 |
皮肤病学 | 423篇 |
神经病学 | 2092篇 |
特种医学 | 1127篇 |
外国民族医学 | 12篇 |
外科学 | 3217篇 |
综合类 | 221篇 |
一般理论 | 6篇 |
预防医学 | 1603篇 |
眼科学 | 775篇 |
药学 | 1403篇 |
中国医学 | 43篇 |
肿瘤学 | 1140篇 |
出版年
2021年 | 313篇 |
2020年 | 196篇 |
2019年 | 260篇 |
2018年 | 345篇 |
2017年 | 279篇 |
2016年 | 305篇 |
2015年 | 387篇 |
2014年 | 486篇 |
2013年 | 712篇 |
2012年 | 907篇 |
2011年 | 879篇 |
2010年 | 587篇 |
2009年 | 572篇 |
2008年 | 825篇 |
2007年 | 913篇 |
2006年 | 861篇 |
2005年 | 833篇 |
2004年 | 798篇 |
2003年 | 701篇 |
2002年 | 755篇 |
2001年 | 713篇 |
2000年 | 723篇 |
1999年 | 645篇 |
1998年 | 351篇 |
1997年 | 322篇 |
1996年 | 297篇 |
1995年 | 233篇 |
1994年 | 226篇 |
1993年 | 169篇 |
1992年 | 428篇 |
1991年 | 451篇 |
1990年 | 425篇 |
1989年 | 402篇 |
1988年 | 417篇 |
1987年 | 368篇 |
1986年 | 368篇 |
1985年 | 327篇 |
1984年 | 253篇 |
1983年 | 189篇 |
1982年 | 155篇 |
1981年 | 141篇 |
1980年 | 146篇 |
1979年 | 227篇 |
1978年 | 171篇 |
1977年 | 173篇 |
1976年 | 162篇 |
1975年 | 162篇 |
1974年 | 176篇 |
1973年 | 146篇 |
1972年 | 146篇 |
排序方式: 共有10000条查询结果,搜索用时 895 毫秒
21.
A. Meyer 《European archives of oto-rhino-laryngology》1940,147(1):66-68
Ohne ZusammenfassungGottesbergeMit 1 Textabbildung 相似文献
22.
Parastoo Jangouk Thomas Dehmel Gerd Meyer Zu Hörste Andreas Ludwig Helmar C. Lehmann Bernd C. Kieseier 《Glia》2009,57(16):1765-1774
The disintegrin and metalloproteinase 10 (ADAM10) is a membrane‐anchored metalloproteinase with both proteolytic and disintegrin characteristics. Here, we investigate the expression, regulation, and functional role of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. Expression pattern analysis of 11 ADAM family members in co‐cultures of rat dorsal root ganglia (DRG) neurons and Schwann cells (SCs) demonstrated the most pronounced mRNA expression for ADAM10. In further studies, ADAM10 was found to be consistently upregulated in DRG‐SC co‐cultures before the induction of myelination. Neurons as well as SCs widely expressed ADAM10 at the protein level. In neurons, the expression of ADAM10 was exclusively limited to the axons before the induction of myelination. Inhibition of ADAM10 activity by the hydroxamate‐based inhibitors GI254023X and GW280264X resulted in a significant decrease in the mean axonal length. These data suggest that ADAM10 represents a prerequisite for myelination, although its activity is not required during the process of myelination itself as demonstrated by expression analysis of myelin protein zero (P0) and Sudan black staining. Hence, during the process of myelin formation, ADAM10 is highly upregulated and appears to be critically involved in axonal outgrowth that is a requirement for myelination in the peripheral nerve. © 2009 Wiley‐Liss, Inc. 相似文献
23.
24.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
25.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
26.
27.
J A Gottridge B R Meyer N S Schwartz R S Lesser 《Archives of internal medicine》1989,149(7):1660-1662
To determine the value of chest roentgenograms in the management of asymptomatic persons with positive tuberculin skin test results, we undertook a retrospective review of all tests administered by our Employee Health Service, North Shore University Hospital, Manhasset, NY, between July 1, 1983 and November 1, 1987. Of 5200 tests, 247 results were positive. Two hundred twenty-one of these charts were reviewed for roentgenographic results and the presence of symptoms. All persons were asymptomatic. Chest roentgenograms revealed the following: normal, 188; unrelated abnormalities, 24; apical pleural thickening, 5; granulomas, 2; calcified hilar node, 1; and calcified node plus granuloma, 1. We noted no active tuberculosis, nor did the chest roentgenographic results influence recommendations for isoniazid prophylaxis. We conclude that chest roentgenograms are of value in 0% to 1.3% of asymptomatic people with positive tuberculin test results. A larger study should be undertaken to further define the usefulness of chest roentgenograms in this population. 相似文献
28.
Brain serotonin transporter binding in non-depressed patients with Parkinson's disease 总被引:2,自引:0,他引:2
M. Guttman I. Boileau J. Warsh J. A. Saint-Cyr N. Ginovart T. McCluskey S. Houle A. Wilson E. Mundo P. Rusjan J. Meyer S. J. Kish 《European journal of neurology》2007,14(5):523-528
Early post-mortem data suggest that damage to brain serotonin neurones might play a role in some features (e.g., depression) of Parkinson's disease (PD). However, it is not known whether such damage is a typical characteristic of living patients with PD or whether the changes are regionally widespread. To address this question we measured, by positron emission tomography imaging, levels of the brain serotonin transporter (SERT), a marker for serotonin neurones, as inferred from binding of [11 C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB), a second generation SERT radioligand, in subcortical and cerebral cortical brain areas of clinically advanced non-depressed (confirmed by structured psychiatric interview) patients with PD. SERT binding levels in PD were lower than those in controls in all examined brain areas, with the changes statistically significant in orbitofrontal cortex (−22%), caudate (−30%), putamen (−26%), and midbrain (−29%). However, only a slight non-significant reduction (−7%) was observed in dorsolateral pre-frontal cortex, an area implicated in major depression. Our imaging data suggests that a modest, regionally widespread loss of brain serotonergic innervation might be a common feature of advanced PD. Further investigation will be required to establish whether SERT binding is more or less decreased in those patients with PD who also have major depressive disorder. 相似文献
29.
C Van Hartesveldt G A Cottrell M E Meyer 《Pharmacology, biochemistry, and behavior》1989,33(2):321-324
The effects of intracerebral implants of 17 beta estradiol and cholesterol in five brain regions were tested on the duration of the dorsal immobility response in ovariectomized female rats. The dorsal immobility response was significantly prolonged by 4-hr implants of 17 beta estradiol in the dorsal striatum and nucleus accumbens, but not in the cortex, the globus pallidus, or the substantia nigra pars compacta. These data further support previous evidence that estradiol acts directly on the striatum to affect behavior in the rat. 相似文献
30.